Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms (VIP-HANA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03182738 |
Recruitment Status :
Completed
First Posted : June 9, 2017
Results First Posted : December 13, 2019
Last Update Posted : December 13, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV (Human Immunodeficiency Virus) AIDS (Acquired Immunodeficiency Syndrome) | Behavioral: VIP app without HIV-related symptom strategies. Behavioral: VIP app that delivers HIV-related symptom strategies. | Not Applicable |
As PLWHA age, they are developing chronic illnesses and co-morbid conditions that are often seen in older HIV negative patients. HANA conditions (e.g., cardiovascular disease, liver disease, diabetes, and asthma) are becoming more common as PLWHA age.
An individual's ability to identify and self-manage symptoms of HIV illness has been shown to improve patient outcomes and quality of life. The investigators will develop and pilot test the Video Information Provider (VIP), a web application (app) that delivered HIV-related symptom self-care strategies for PLWHA for 13 common (non-HANA) HIV/AIDS symptoms. There is a need to identify the symptom experience of PLWHA with HANA conditions.
The aim is to compare the efficacy of VIP-HANA to a control arm for ameliorating symptom frequency and intensity and secondary health outcomes in 100 PLWHA with HANA conditions over 6 months.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Supportive Care |
Official Title: | Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms |
Actual Study Start Date : | November 16, 2016 |
Actual Primary Completion Date : | April 3, 2019 |
Actual Study Completion Date : | May 31, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Intervention
VIP app that delivers HIV-related symptom strategies
|
Behavioral: VIP app that delivers HIV-related symptom strategies.
The Intervention group will receive the VIP app that delivers HIV-related symptom strategies |
Sham Comparator: Control
VIP app without HIV-related symptom strategies
|
Behavioral: VIP app without HIV-related symptom strategies.
The control group will receive the VIP app without HIV-related symptom strategies |
- Symptom Burden Score [ Time Frame: Baseline, 3 months and 6 months; period 1 = 1-6 weeks (baseline), period 2 = 6-18 weeks (3 months), period 3 = >18 weeks (6 months) ]The Symptom Burden Score is an expanded version of the 20-item HIV symptom index. The score is calculated for the 28 most common symptoms in persons living with HIV. Each symptom is given a score ranging from 0 to 4 with the scores indicating the following: 0 (not experienced) , 1 (It doesn't bother me), 2 (It bothers me a little), 3 (It bothers me), or 4 (It bothers me a lot). The higher the score (closer to 4), the greater the symptom burden (worse outcome).
- Score on Patient-Reported Outcomes Measurement Information System® (PROMIS)-29 [ Time Frame: Baseline, 3 months, and 6 months ]The PROMIS-29 includes seven health related quality of life domains (Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain), and the pain domain has two subdomains (interference and intensity). Each of the 7 domains has four 5-level items (i.e., 16 decrements each). In addition to these items, pain intensity is assessed using a single 11-point numeric rating scale anchored between no pain (0) and worse imaginable pain. Raw scores, except pain intensity, are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. T-scores can be estimated using scoring tables listed in the PROMIS manuals. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on physical function indicates better functioning, whereas a higher score on depression indicates more severe depressive symptoms.
- Change in Score on SF-12 [ Time Frame: 3 months and 6 months ]12-Item Medical Outcomes Study Short Form (SF-12) is a health survey to measure health-related quality of life.
- Score on Engagement With Health Care Provider Scale [ Time Frame: Baseline, 3 months, and 6 months ]Engagement with Health Care Provide scale is a 13-item scale in which subjects rate their interactions with their health care providers on a four-point scale with 1=always true and 4=never true. A total score can be calculated to create a possible range of 13-52. A low score (closer to 13) indicates greater provider engagement between the patient and provider.
- Score of the VAS [ Time Frame: Baseline, 3 months, and 6 months ]The Visual Analogue Scale (VAS) measures adherence to antiretroviral therapy (ART). VAS asks subjects to indicate a point on a line that shows their best guess about how much of each drug they have taken. 0% means they have taken no drug, 50% means they have taken half their drugs, and 100% means they have taken every single dose.
- Score on Fried's Frailty Phenotype [ Time Frame: Baseline, 3 months, and 6 months ]Fried's frailty phenotype is a combination of five scores: weight loss in the last year, exhaustion, physical activity, walk time for a 15 foot interval, and grip strength. The frailty condition is defined as meeting the definition of frailty for at least 3 of the listed scores.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV+
- Age 18 or over
- Able to read and respond in English
- Reside within the US
- Willing to participate in an online survey.
Exclusion Criteria:
- HIV-negative
- under age 18
- Unwilling to provide key data (i.e., age, information about symptoms) on the online survey.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03182738
United States, New York | |
Columbia University School for Nursing | |
New York, New York, United States, 10032 |
Principal Investigator: | Rebecca Schnall, PhD | Columbia University |
Documents provided by Rebecca Schnall, RN, MPH, PhD, Columbia University:
Responsible Party: | Rebecca Schnall, RN, MPH, PhD, Assistant Professor of Nursing, Columbia University |
ClinicalTrials.gov Identifier: | NCT03182738 |
Other Study ID Numbers: |
AAAP5958 R01NR015737-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | June 9, 2017 Key Record Dates |
Results First Posted: | December 13, 2019 |
Last Update Posted: | December 13, 2019 |
Last Verified: | November 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
HIV/AIDS Health Management App HIV/AIDS symptoms |
Acquired Immunodeficiency Syndrome HIV Infections Immunologic Deficiency Syndromes Immune System Diseases Blood-Borne Infections Communicable Diseases Infections |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Slow Virus Diseases |